Tysabri Backlash: GSK’s Phase II Multiple Sclerosis Drug On Clinical Hold
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK drug is a dual alpha-4 integrin antagonist, the same mechanism of action as Tysabri. Biogen Idec/Elan suspended Tysabri marketing based on a safety signal. GSK had expected to file an NDA for ’699 in 2008.